Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Ekso Bionics Holdings (EKSO) EBITDA (2016 - 2025)

Historic EBITDA for Ekso Bionics Holdings (EKSO) over the last 14 years, with Q3 2025 value amounting to -$1.4 million.

  • Ekso Bionics Holdings' EBITDA rose 4467.1% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.1 million, marking a year-over-year increase of 595.68%. This contributed to the annual value of -$10.5 million for FY2024, which is 3252.8% up from last year.
  • As of Q3 2025, Ekso Bionics Holdings' EBITDA stood at -$1.4 million, which was up 4467.1% from -$3.8 million recorded in Q2 2025.
  • In the past 5 years, Ekso Bionics Holdings' EBITDA ranged from a high of -$1.4 million in Q2 2021 and a low of -$4.6 million during Q1 2023
  • In the last 5 years, Ekso Bionics Holdings' EBITDA had a median value of -$3.1 million in 2024 and averaged -$3.1 million.
  • Examining YoY changes over the last 5 years, Ekso Bionics Holdings' EBITDA showed a top increase of 8831.1% in 2021 and a maximum decrease of 18330.88% in 2021.
  • Quarter analysis of 5 years shows Ekso Bionics Holdings' EBITDA stood at -$2.6 million in 2021, then tumbled by 55.69% to -$4.1 million in 2022, then increased by 7.56% to -$3.8 million in 2023, then skyrocketed by 34.9% to -$2.5 million in 2024, then surged by 41.73% to -$1.4 million in 2025.
  • Its EBITDA was -$1.4 million in Q3 2025, compared to -$3.8 million in Q2 2025 and -$3.4 million in Q1 2025.